Windward Bio priced 10,294,117 shares at $17 on 12 November, the midpoint of its $16–$18 range.
The stock began trading on the Nasdaq Global Select Market as WWB on 13 November.
Read all 5 points
Sanofi separately took $50 million of shares and pre-funded warrants, taking expected gross proceeds to $225 million.
Rezera postponed its planned $200 million Nasdaq IPO of 16.7 million shares at $11–$13, citing market conditions.
Windward paid $70 million upfront for its two licensed programmes, with up to $1.6 billion in milestones.
Written by Claude from this page's own figures at 16 Nov, 06:04 am IST — every number checked against the page. A summary, not advice.
What happened
Windward Bio priced 10,294,117 shares at $17 on 12 November, the midpoint of its $16–$18 range, and began trading on the Nasdaq Global Select Market as WWB on 13 November. Sanofi separately bought $50 million of shares and pre-funded warrants at the IPO price, taking expected gross proceeds to $225 million before the underwriters' option on 1,544,117 more shares. On the evening of 11 November, Boston-based Rezera, formerly NodThera, postponed its planned $200 million Nasdaq IPO of 16.7 million shares at $11–$13, citing market conditions.
Why it matters for listed companies
The two deals show how selective the US biotech IPO window is: a company with a late-stage asthma antibody and a big-pharma backer priced in its range, while another, with an earlier-stage NLRP3 programme and GSK's indicated interest of up to $25 million, stepped back. Windward paid $70 million upfront for its two licensed programmes, with up to $1.6 billion in milestones, so the IPO money funds trials and licence payments. Banks on both books (Jefferies, TD Cowen) earn fees only on deals that price.
Official series on 13 Nov 2026 or the last day before it, and the latest observation.
US Treasury 2-year yield 4.88% → 4.83%-5 bp 13 Nov 2026 → 16 Nov 2026 · US Treasury
US Treasury 10-year yield 5.15% → 5.12%-3 bp 13 Nov 2026 → 16 Nov 2026 · US Treasury
Euro in US dollars 1.1052 → 1.1014-0.0038 13 Nov 2026 → 16 Nov 2026 · ECB reference rate
These figures are measured, not attributed. Prices and rates move for many reasons at once; they show
what happened after this story, not that the story caused it. Nothing here is a recommendation to buy, sell or hold.
Option Care gives infusion drugs at home and in clinics instead of hospitals, a channel insurers favour because it costs less. McKesson, which already distributes specialty drugs, gains a stake in the provider that…
The advance was narrow: the report notes only about 25% of S&P 500 companies were trading above their 50-day average, and smaller companies fell on the day. Index gains are coming from AI chipmakers and from power…
Information Technology · Utilities · Health CareYahoo Finance ↗
Epcoritamab, sold as EPKINLY in the US and Japan and TEPKINLY in the EU, is approved so far for lymphoma that has returned after earlier treatment. A first-line label would open a much larger group of patients, and…
These are the first US deals to launch in the fourth quarter, and both are small, clinical-stage companies with no product revenue: the money funds trials. TRex Bio's lead programme has topline data due in mid-2027 and…